{"url_path":"/sec/hura/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1498382/0001193125-26-227245-index.html","accession_number":"0001193125-26-227245","cik":"0001498382","ticker":"HURA","issuer_name":"TuHURA Biosciences, Inc./NV","edgar_url":"https://www.sec.gov/Archives/edgar/data/1498382/0001193125-26-227245-index.html","primary_entity_key":"0001498382","primary_entity_name":"TuHURA Biosciences, Inc./NV"},"word_count":135,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\n(a)\n\nOn May 15, 2026, the Company and Parkview Holdings One LLC (“Parkview”) entered into a First Amendment to Loan Agreement (the “Amendment”) which amends the Company’s Loan Agreement dated April 21, 2026, with Parkview (the “Loan Agreement”). The Amendment clarifies that the restriction on selling or issuing equity interests set forth in Section 7.05 of the Loan Agreement does not apply to sales or issuances of the capital stock of the Company.\n\n(b) None.\n\n(c) Director and Officer Trading Arrangements\n\nNone of our directors or officers, as defined in Rule 16a-1(f) under the Exchange Act, adopted or terminated a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K, during the three months ended March 31, 2026.\n\n \n\n26"}